Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value
$47.89+1.42 (+3.06%)
Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –
Alkermes total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Alkermes's total debt was $1.50B at Jun 30, 2026. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $444.46M in fiscal 2012.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $290.73M | -0.9% |
| FY2022 | Dec 31, 2022 | $293.27M | -0.9% |
| FY2021 | Dec 31, 2021 | $295.80M | +7.6% |
| FY2020 | Dec 31, 2020 | $274.96M | -0.8% |
| FY2019 | Dec 31, 2019 | $277.14M | -0.8% |
| FY2018 | Dec 31, 2018 | $279.31M | -0.8% |
| FY2017 | Dec 31, 2017 | $281.44M | -0.8% |
| FY2016 | Dec 31, 2016 | $283.67M | -18.9% |
| FY2015 | Dec 31, 2015 | $349.94M | -5.2% |
| FY2013 | Mar 31, 2013 | $369.01M | -17.0% |
| FY2012 | Mar 31, 2012 | $444.46M | – |
| FY2011 | Mar 31, 2011 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.50B | +419.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.51B | +420.6% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $288.82M | -0.9% |
| Q2 FY2024 | Jun 30, 2024 | $289.46M | -0.9% |
| Q1 FY2024 | Mar 31, 2024 | $290.10M | -0.9% |
| Q4 FY2023 | Dec 31, 2023 | $290.73M | -0.9% |
| Q3 FY2023 | Sep 30, 2023 | $291.37M | -0.9% |
| Q2 FY2023 | Jun 30, 2023 | $292.00M | -0.9% |
| Q1 FY2023 | Mar 31, 2023 | $292.64M | -0.9% |
| Q4 FY2022 | Dec 31, 2022 | $293.27M | -0.9% |
| Q3 FY2022 | Sep 30, 2022 | $293.90M | -0.9% |
| Q2 FY2022 | Jun 30, 2022 | $294.54M | -0.9% |
| Q1 FY2022 | Mar 31, 2022 | $295.17M | -0.9% |
| Q4 FY2021 | Dec 31, 2021 | $295.80M | +7.6% |
| Q3 FY2021 | Sep 30, 2021 | $296.44M | +7.6% |
| Q2 FY2021 | Jun 30, 2021 | $297.07M | +7.6% |
| Q1 FY2021 | Mar 31, 2021 | $297.70M | +7.6% |
| Q4 FY2020 | Dec 31, 2020 | $274.96M | -0.8% |
| Q3 FY2020 | Sep 30, 2020 | $275.51M | -0.8% |
| Q2 FY2020 | Jun 30, 2020 | $276.05M | -0.8% |
| Q1 FY2020 | Mar 31, 2020 | $276.59M | -0.8% |
| Q4 FY2019 | Dec 31, 2019 | $277.14M | -0.8% |
| Q3 FY2019 | Sep 30, 2019 | $277.68M | -0.8% |
| Q2 FY2019 | Jun 30, 2019 | $278.22M | -0.8% |
| Q1 FY2019 | Mar 31, 2019 | $278.77M | -0.8% |
| Q4 FY2018 | Dec 31, 2018 | $279.31M | -0.8% |
| Q3 FY2018 | Sep 30, 2018 | $279.85M | -0.8% |
| Q2 FY2018 | Jun 30, 2018 | $280.39M | -0.8% |
| Q1 FY2018 | Mar 31, 2018 | $280.93M | -0.8% |
| Q4 FY2017 | Dec 31, 2017 | $281.44M | -0.8% |
| Q3 FY2017 | Sep 30, 2017 | $281.99M | -1.3% |
| Q2 FY2017 | Jun 30, 2017 | $282.55M | – |
| Q1 FY2017 | Mar 31, 2017 | $283.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $283.67M | – |
| Q3 FY2016 | Sep 30, 2016 | $285.58M | – |
See a number that looks wrong?